Table 2 PD-L1 assay interpretation guidelines and scoring
Antibody | Site/tumor type | Interpretation guidelines [positive]a |
|---|---|---|
22C3 | Gastroesophageal | Combined positive score (CPS); [Tumor + immune cells = > 1%] |
Other sites | Tumor proportion score (TPS); [Tumor = > 1% expression; tumor = > 50% high expression] | |
28-8 | [Tumor cells > 1%] | |
NSCLC | PD-L1 expression [tumor = > 1%; tumor = > 5%; tumor = > 10%b] | |
HNSCC | PD-L1 expression [Tumor cells > 1%] | |
Urothelial | PD-L1 expression [Tumor cells > 1%] | |
Melanoma | PD-L1 expression [Tumor cells > 1%] | |
SP142 | Urothelial | PD-L1 expression [ = > 5% in tumor-infiltrating immune cells] |
NSCLC | PD-L1 expression [Tumor cell = > 50% or Immune cell = > 10%] | |
SP263 | Urothelial | PD-L1 status [Tumor cells = > 25% OR Immune cells present > 1% and tumor associated immune cell staining = > 25% OR Immune cells present = 1% and tumor associated immune cell staining 100%: PD-L1 status – high] |
NSCLC | PD-L1 IHC score [Tumor cells = > 1%] |
